Modality
Degrader
MOA
AuroraAi
Target
Aβ
Pathway
Innate Imm
ALLOvarian CaIPF
Development Pipeline
Preclinical
Jan 2021
→ Feb 2025
PreclinicalCurrent
NCT07996521
909 pts·ALL
2021-01→2025-02·Completed
909 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-02-101.1y agoInterim· ALL
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025
Preclinical
Complet…
Catalysts
Interim
2025-02-10 · 1.1y ago
ALL
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07996521 | Preclinical | ALL | Completed | 909 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 |